首页> 外文期刊>Schizophrenia research and treatment >Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
【24h】

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial

机译:第二代抗精神病药改善精神分裂症的性功能障碍:随机对照试验。

获取原文
           

摘要

The impact of antipsychotic drug treatment on sexual function was investigated during a randomised trial comparing first generation antipsychotics (FGAs) to (nonclozapine) second generation antipsychotics (SGAs). Sexual function and quality of life were (rater-blind) assessed in 42 patients with DSM-IV schizophrenia (aged 18–65) using the self-report version of the Derogatis Interview for Sexual Function (DISF-SR) and the Heinrichs Quality of Life Scale (QLS), prior to, and 12 weeks following, a change in medication from an FGA drug to either an FGA or SGA drug. SGAs significantly improved sexual function compared to FGAs. Change in sexual function was associated with change in quality of life. Where impaired sexual functioning is a distressing adverse effect of treatment with an FGA agent, consideration should be given to switching to an SGA.
机译:在比较第一代抗精神病药(FGA)与(非氯氮平)第二代抗精神病药(SGA)的随机试验中,研究了抗精神病药治疗对性功能的影响。使用Derogatis性功能访谈(DISF-SR)的自我报告版本和Heinrichs的质量评价(DSF-IV精神分裂症患者(18-65岁))对42名DSM-IV精神分裂症患者的性功能和生活质量进行了评估(盲人)。从FGA药物改为FGA或SGA药物之前和之后12周的生活量表(QLS)。与FGA相比,SGA显着改善了性功能。性功能的改变与生活质量的改变有关。如果性功能障碍是使用FGA剂治疗的令人痛苦的不利影响,则应考虑改用SGA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号